AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00800618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02413873 100 mg QD
Description: 100 mg of PF-02413873 oral suspension once daily for 14 days
Study NCT00800618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02413873 1500 mg QD
Description: 1500 mg of PF-02413873 oral suspension once daily for 14 days
Study NCT00800618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02413873 20 mg QD
Description: 20 mg of PF-02413873 oral suspension once daily for 14 days
Study NCT02094794 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic peripheral blood stem cell or bone marrow transplant
Study NCT00970710 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vaasa Childhood Obesity Primary Prevention Study
Description: Intensified counselling concerning healthy diet and suitable physical activity during pregnancy to mothers in the intervention group continuing in child health care clinic visits with the offspring until child's age of 5 year.
Study NCT02094794 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Undergo allogeneic peripheral blood stem cell or bone marrow transplant
Study NCT02808884 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Circulating tumor DNA assay
Description: Blood samples will be separated into plasma and cellular fraction including erythrocytes and buffy coat.The plasma fraction will be placed in a separate tube and frozen for subsequent analysis. Frozen plasma samples, de-identified, will be delivered to Pathway Genomics where DNA content will be analyzed with a circulating tumor DNA assay employing the UBC/Boreal Genomics enrichment technology. All of the participants' plasma will be sent to Pathway, where it will be used up in the assay. Circulating tumor DNA assay results (raw sequencing data) from Pathway Genomics will be returned to UBC and analyzed for the presence of cancer mutations. Any samples showing activating mutations above the assay's technical Limit of Detection (LOD) will be called positive. One exception will be made for TP53 mutations that are known to exist in some normal individuals at low levels. For these mutations, a level of 0.1% will be set, above which the sample will be called positive.
Study NCT00800618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02413873 500 mg QD
Description: 500 mg of PF-02413873 oral suspension once daily for 14 days
Study NCT00800618 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-02413873 Placebo
Description: PF-0241383 Placebo once daily for 14 days
Study NCT03878264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335 Oral
Description: CORT118335 900 mg spray-dried dispersion in bottle and vehicle for oral administration
Study NCT03878264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-CORT118335 intravenous
Description: 14C-CORT118335 solution for infusion 100 µg containing not more than 37 kiloBequerel (1 µCi) 14C
Study NCT03878264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-CORT118335 oral
Description: 14C-CORT118335 oral solution 150 mg containing not more than 3.3 megaBequerel (90 µCi) 14C
Study NCT02093871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ThermalCore Hyperthermia System
Description: Patients will undergo 6 cycles of therapeutic hyperthermia with the ThermalCore Perfusion Induced Systemic Hyperthermia System every 28 days
Study NCT02671292 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy
Description: IPT-WG involves one initial 1.5-hour individual session, and 12 weekly 90-minute group sessions. The IPT-WG group sessions follow 3 phases (initial, middle, and termination) and use the interpersonal inventory to identify interpersonal problems that might be contributing to or exacerbated by LOC eating. A framework of common problem areas is used to teach interpersonal problem-solving and communication skills and educate youth about risk factors for excessive weight gain and warning signs such as eating in response to negative affect as opposed to hunger, or feeling a sense of LOC while eating.
Study NCT02671292 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: The HE group is based upon the HEY-Durham health program designed by researchers at Duke University. This program, designed to be delivered to youth attending community high schools, was adapted to a 12-week program (each session is 90 minutes). Additionally, individuals will attend a pre-group individual meeting with the group leaders to review family health history.The curriculum includes focus on various health topics, including alcohol, drug and tobacco use, depression and suicide, nutrition and body image, nonviolent conflict resolution, sun safety, exercise, and domestic violence. Session content will be largely identical for boys and girls, with the exception of gender-specific videos and articles (e.g., on body image), which will be tailored for each sex.
Study NCT02486354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: icotinib
Description: Patients were administered with oral icotinib (tablet form, 125 mg) three times daily within two days after enrollment until disease progression or unacceptable toxicity.
Study NCT01093534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching solifenacin placebo tablet
Study NCT01093534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching solifenacin placebo tablet
Study NCT01093534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin
Description: Tablet for oral administration
Study NCT00085124 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV
Study NCT00085124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT00085124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV
Study NCT00085124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01436916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral cholecalciferol + life style counselling
Description: oral cholecalciferol 600000 units loading then 60000 units fortnightly for 6months
Study NCT01436916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo + life style counselling
Description: Will provide placebo 10 sachets loading and then single sachet fortnightly for 6 months
Study NCT01791868 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: According to randomization arm, patients will be treated either by intravenous sodium valproate (30 mg/kg during 15 min then 1 mg/kg/h during 12 h) or intravenous placebo. All included patients will benefit from first-line anti epileptic drugs and symptomatic medical care, in agreement with the French Experts Recommendation 2009(RFE 2009).
Study NCT04487288 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SONAZOID
Description: CEUS using SONAZOID with fusion technique
Study NCT02702986 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immunostimulating Interstitial Laser Thermotherapy
Description: Through a laparotomy a laser device will be inserted into the locally advanced pancreatic cancer.
Study NCT02702986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Study NCT04043819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSC-01
Description: PSC-01 is a form of autologous cellular therapy resulting from the enzymatic processing of lipoaspirate to yield adipose-derived stromal vascular fraction cells.
Study NCT02209675 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: liver biopsy
Description: C4d assessment by immunohistchemistry in liver biopsy
Study NCT00200746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine
Description: Amino Acid Arginine
Study NCT00498316 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cord Blood Infusion
Description: Cord blood transplantation performed on day 0.
Study NCT00498316 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan
Description: 32 mg/m2 by vein as an outpatient before Day -14 or as an inpatient on Day -9, and AUC of 4,000 microMol.min-1 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are >1 and \< 55 years old. Patients >55 but \< 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).
Study NCT00200746 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Arginine
Description: Amino Acid Arginine
Study NCT03238742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xuebijing Injection
Description: 100ml Xuebijing Injection every 12 hours for 5 days
Study NCT01344655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atimos®
Description: Formoterol 12 μg pMDI
Study NCT03938376 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Micro-Ultrasound guided biopsy
Description: High-resolution imaging device
Study NCT03238742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 200ml normal saline every 12 hours for 5 days
Study NCT01344655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Serevent™
Description: Salmeterol 25 µg pMDI
Study NCT01344655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT03250429 — intervention group
Intervention type: PROCEDURE
Intervention: Sinus surgery
Description: Standard Clinical Sinus Surgery
Study NCT05768971 — intervention group
Intervention type: OTHER
Intervention: Mild diet
Study NCT05768971 — intervention group
Intervention type: OTHER
Intervention: Provocative diet
Study NCT04625790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Transcranial Magnetic Stimulation(TMS) has been used for diagnostic and therapeutic purposes in the treatment of many neurological and psychiatric diseases such as stroke, multiple sclerosis, myelopathy, amyotrophic lateral sclerosis, movement disorders, epilepsy, and depression. It is a way to stimulate the targeted areas in the cerebral cortex without invasive methods. The application of TMS in the aphasia usually consists of repetitive stimulations, in order to activate or deactivate the target area.~In this study, 10 sessions of 1-Hz low frequency rTMS for 20 minutes will be applied to the inferior frontal gyrus of the right frontal lobe.
Study NCT04625790 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Speech therapy
Description: Speech therapy will be given to each patient by the same therapist, and the treatment will last 10 days, 60 minutes a day. It will consist of exercises to improve the articulation and comprehension.
Study NCT04625790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speech therapy
Description: Speech therapy will be given to each patient by the same therapist, and the treatment will last 10 days, 60 minutes a day. It will consist of exercises to improve the articulation and comprehension.
Study NCT00145704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bisphosphonate therapy (risedronate)
Description: Bisphosphonate therapy given to patients with growth hormone deficiency
Study NCT00145704 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D supplement
Description: Vitamin D given to patients with growth hormone deficiency
Study NCT00145704 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D supplement
Description: Vitamin D given to patients with growth hormone deficiency
Study NCT00145704 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: calcium supplement given to patients with growth hormone deficiency
Study NCT00145704 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: calcium supplement given to patients with growth hormone deficiency
Study NCT04447417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous
Study NCT01614600 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nelfilcon A contact lenses
Description: Commercially marketed hydrogel contact lenses for daily wear, daily disposable use
Study NCT04618692 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Loupes
Description: Biliary reconstruction will be performed using surgical loupe
Study NCT04618692 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microscope
Description: Biliary reconstruction will be performed using microscope
Study NCT01180374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Active Cannabidiol 5mg.
Study NCT00729755 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate
Description: In addition to 10-20mg escitalopram, the subjects will be given total 3 gram of creatine (500mg/capsule) a day in first week and then, 5 gram a day in the rest of the weeks.
Study NCT00729755 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In addition to 10-20mg escitalopram, the subjects will be given total 6 capsules of placebo (equal quantities to those of creatine group) a day in first week and then, 10 capsules a day in the rest of the weeks.
Study NCT03855956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KB174
Description: KB174 is a novel mixture of oligosaccharides.
Study NCT03855956 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Maltodextrin
Description: Maltodextrin is a commercially available easily digestible polysaccharide.
Study NCT01645137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: osteopathic manipulative treatment
Description: Patients from this group received osteopathic treatments twice a week for the entire length of stay in the unit.
Study NCT01645137 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
Study NCT00498316 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine
Description: 10 mg/m2 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are >1 and \< 55 years old. Patients >55 but \< 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).~40 mg/m2 by vein on Days -6 to -3 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are > 55 and \< 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.~40 mg/m2 by vein on Days -5 to -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are >1 and \< 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3.
Study NCT00498316 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab
Description: 375 mg/m2 by vein on Day -9 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are > 55 and \< 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.
Study NCT00498316 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ATG
Description: 1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are > 55 and \< 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.~1.25 mg/kg by vein on Day -3 and 1.75 mg/kg by vein on Day -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are >1 and \< 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3.
Study NCT00498316 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: 50 mg/kg by vein on Day -6 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are > 55 and \< 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.
Study NCT00498316 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clofarabine
Description: 30 mg/m2 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are >1 and \< 55 years old. Patients >55 but \< 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).
Study NCT00498316 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Total Body Irradiation (TBI)
Description: 200 cGy at 25 cGy/minute delivered on Day -3.
Study NCT00498316 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Melphalan
Description: 140 mg/m2 by vein on Day -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are >1 and \< 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3.
Study NCT00498316 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tacrolimus
Description: 0.03 mg/kg by vein daily starting on D-2, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered around Day +180, if no GVHD is present.
Study NCT00498316 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mycophenolate Mofetil
Description: 1 gram by vein twice a day Days -3 through Day 100.
Study NCT00498316 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: G-CSF
Description: 5 mcg/kg/day subcutaneously beginning on day 0, and continuing until the absolute neutrophil count (ANC) is > 2.5 x 109/L.
Study NCT04505735 — intervention group
Intervention type: DRUG
Intervention: 11C-PiB
Description: Pittsburgh Compound-B (11C-PiB) is a diagnostic imaging agent that binds to beta-amyloid plaques and allows them to be viewed using positron emission tomography (PET) imaging.
Study NCT00905827 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAMS
Description: Collaborative assessment management in suicidality
Study NCT03725215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Split-Belt Treadmill Training
Description: One session of 6 x 5 min with 1 min intervals.
Study NCT03725215 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Split-Belt Treadmill Training
Description: One session of 6 x 5 min with 1 min intervals.
Study NCT01892215 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cephalad-caudad expansion
Description: Blunt expansion of the uterine incision by the physician separating the fingers in a cephalad-caudad direction.
Study NCT01892215 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversal expansion
Description: Blunt expansion of the uterine incision by the physician separating the fingers in a transversal direction.
Study NCT00894023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intracoronary bolus wtih ClearWay™RX catheter
Description: Intracoronary bolus with Clearway catheter
Study NCT00894023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV abciximab
Description: IV abciximab + infusion
Study NCT06403215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing gum group
Description: Women in this group chewed sugar-free and non-xylite gum for 15 minutes every two hours (2nd, 4th, and 6th) following the cesarean operation.
Study NCT06403215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fennel tea group
Description: Women in this group started oral intake 6 hours after cesarean delivery and were allowed to drink 2 grams of fennel tea in the 6th, 8th, and 10th hours (a total of 6 grams of fennel tea).
Study NCT06403215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing gum+Fennel tea group
Description: Women in this group both chewed sugar-free and non-xylite gum for 15 minutes every two hours (2nd, 4th, and 6th) following the cesarean operation and started oral intake 6 hours after cesarean delivery and were allowed to drink 2 grams of fennel tea in the 6th, 8th, and 10th hours (a total of 6 grams of fennel tea).
Study NCT06403215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: No intervention
Study NCT03222037 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Description: Acuvue Oasys 1-Day
Study NCT03222037 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control
Description: Trial Frame with best spherocylindrical refraction (SCR)
Study NCT04164758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: Pimavanserin 34 mg (provided as 2×17 mg encapsulated tablets) administered orally as a single dose once daily
Study NCT04164758 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (provided as 2 × placebo encapsulated tablets) administered orally as a single dose once daily